ROR1 and neoplasm: To evaluate the safety and anti-tumor effects of autologous anti-ROR1 CAR-T cells, a phase I clinical study (NCT02706392) conducted by the Fred Hutchinson Cancer Research Center involved patients with advanced, ROR1-positive, stage IV NSCLC (287).